TT International Asset Management LTD Reduces Position in Gilead Sciences, Inc. (NASDAQ:GILD)

TT International Asset Management LTD lessened its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 68.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 4,675 shares of the biopharmaceutical company’s stock after selling 10,325 shares during the quarter. TT International Asset Management LTD’s holdings in Gilead Sciences were worth $431,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also modified their holdings of GILD. nVerses Capital LLC bought a new stake in Gilead Sciences during the 3rd quarter valued at approximately $25,000. Valued Wealth Advisors LLC increased its stake in Gilead Sciences by 101.9% in the 3rd quarter. Valued Wealth Advisors LLC now owns 319 shares of the biopharmaceutical company’s stock worth $27,000 after acquiring an additional 161 shares during the last quarter. Cedar Wealth Management LLC increased its stake in Gilead Sciences by 51.6% in the 2nd quarter. Cedar Wealth Management LLC now owns 470 shares of the biopharmaceutical company’s stock worth $32,000 after acquiring an additional 160 shares during the last quarter. Strategic Investment Solutions Inc. IL bought a new stake in Gilead Sciences in the 2nd quarter worth approximately $33,000. Finally, Quarry LP bought a new position in shares of Gilead Sciences during the 2nd quarter valued at approximately $43,000. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Gilead Sciences Trading Up 0.8 %

Shares of NASDAQ GILD opened at $89.88 on Monday. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.26 and a quick ratio of 1.10. The stock has a market capitalization of $112.01 billion, a P/E ratio of 998.67, a price-to-earnings-growth ratio of 2.24 and a beta of 0.18. Gilead Sciences, Inc. has a 1-year low of $62.07 and a 1-year high of $98.90. The business has a fifty day moving average price of $91.94 and a 200 day moving average price of $83.39.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share for the quarter, topping analysts’ consensus estimates of $1.58 by $0.44. The firm had revenue of $7.55 billion during the quarter, compared to analysts’ expectations of $7.01 billion. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. The firm’s quarterly revenue was up 7.0% on a year-over-year basis. During the same period in the prior year, the business posted $2.29 EPS. Equities research analysts expect that Gilead Sciences, Inc. will post 4.36 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Monday, December 30th. Investors of record on Friday, December 13th were given a dividend of $0.77 per share. This represents a $3.08 annualized dividend and a yield of 3.43%. The ex-dividend date was Friday, December 13th. Gilead Sciences’s dividend payout ratio is currently 3,422.22%.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on the company. Wells Fargo & Company boosted their target price on Gilead Sciences from $100.00 to $105.00 and gave the company an “overweight” rating in a research report on Thursday, November 7th. Morgan Stanley raised Gilead Sciences from an “equal weight” rating to an “overweight” rating and boosted their target price for the company from $87.00 to $113.00 in a research report on Friday. Maxim Group downgraded Gilead Sciences from a “buy” rating to a “hold” rating in a research report on Friday, November 8th. Robert W. Baird boosted their target price on Gilead Sciences from $80.00 to $95.00 and gave the company a “neutral” rating in a research report on Thursday, November 7th. Finally, UBS Group boosted their target price on Gilead Sciences from $70.00 to $96.00 and gave the company a “neutral” rating in a research report on Thursday, November 21st. Eleven research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and four have issued a strong buy rating to the company. According to data from MarketBeat.com, Gilead Sciences currently has an average rating of “Moderate Buy” and a consensus target price of $97.96.

Insider Activity at Gilead Sciences

In related news, insider Merdad Parsey sold 25,590 shares of the company’s stock in a transaction dated Wednesday, November 6th. The stock was sold at an average price of $91.50, for a total transaction of $2,341,485.00. Following the transaction, the insider now directly owns 99,599 shares of the company’s stock, valued at $9,113,308.50. This represents a 20.44 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, Director Jeffrey Bluestone sold 6,788 shares of the stock in a transaction dated Tuesday, November 26th. The shares were sold at an average price of $91.39, for a total value of $620,355.32. Following the completion of the transaction, the director now directly owns 8,920 shares in the company, valued at $815,198.80. This represents a 43.21 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 453,734 shares of company stock valued at $41,902,086 in the last ninety days. Corporate insiders own 0.16% of the company’s stock.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.